Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Bello, Maximino | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.contributor.author | Thongprasert, Sumitra | - |
dc.contributor.author | Song, Eun-Kee | - |
dc.contributor.author | Soldatenkova, Victoria | - |
dc.contributor.author | Depenbrock, Henrik | - |
dc.contributor.author | Puri, Tarun | - |
dc.contributor.author | Orlando, Mauro | - |
dc.date.available | 2020-02-27T17:41:32Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5667 | - |
dc.description.abstract | Purpose The phase 3 randomized SQUIRE study revealed significantly longer overall survival (OS) and progression-free survival (PFS) for necitumumab plus gemcitabine and cisplatin (neci+ GC) than for gemcitabine and cisplatin alone (GC) in 1,093 patients with previously untreated advanced squamous non-small cell lung cancer (NSCLC). This post hoc subgroup analysis assessed the efficacy and safety of neci+ GC among East Asian (EA) patients enrolled in the study. Materials and Methods All patients received up to six 3-week cycles of gemcitabine (days 1 and 8, 1,250 mg/m.) and cisplatin (day 1, 75 mg/m.). Patients in the neci+ GC arm also received necitumumab (days 1 and 8, 800 mg) until disease progression or unacceptable toxicity. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated from stratified Cox proportional hazards models. Results In EA patients, there were improvements for neci+ GC (n=43) versus GC (n=41) in OS (HR, 0.805; 95% CI, 0.484 to 1.341) and PFS (HR, 0.720; 95% CI, 0.439 to 1.180), consistent with the results for non-EA patients observed in the present study. The overall safety data were consistent between EA and non-EA patients. A numerically higher proportion of patients experienced serious adverse events (AEs), grade. 3 AEs, and AEs with an outcome of death for neci+ GC versus GC in EA patients and EA patients versus non-EA patients for neci+ GC. Conclusion Although limited by the small sample size and post hoc nature of the analysis, these findings are consistent with those of the overall study and suggest that neci+ GC offers a survival advantage and favorable benefit/risk for EA patients with advanced squamous NSCLC. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.subject | GROWTH-FACTOR RECEPTOR | - |
dc.subject | PROTEIN EXPRESSION | - |
dc.subject | ETHNIC-DIFFERENCES | - |
dc.subject | CLINICAL-TRIALS | - |
dc.subject | III TRIAL | - |
dc.subject | CETUXIMAB | - |
dc.subject | THERAPY | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | METAANALYSIS | - |
dc.subject | MUTATIONS | - |
dc.title | Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000413001500009 | - |
dc.identifier.doi | 10.4143/crt.2016.423 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.49, no.4, pp.937 - 946 | - |
dc.identifier.kciid | ART002271853 | - |
dc.identifier.scopusid | 2-s2.0-85029903629 | - |
dc.citation.endPage | 946 | - |
dc.citation.startPage | 937 | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 49 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Non-small-cell lung carcinoma | - |
dc.subject.keywordAuthor | Cisplatin | - |
dc.subject.keywordAuthor | East Asian | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Necitumumab | - |
dc.subject.keywordAuthor | Epidermal growth factor receptor | - |
dc.subject.keywordPlus | GROWTH-FACTOR RECEPTOR | - |
dc.subject.keywordPlus | PROTEIN EXPRESSION | - |
dc.subject.keywordPlus | ETHNIC-DIFFERENCES | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | III TRIAL | - |
dc.subject.keywordPlus | CETUXIMAB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.